Vulvovaginitis Diagnosis and Treatment

Common Symptoms

• The American Academy of Family Physicians notes that pruritus (itching) in the vulvovaginal area is the most characteristic symptom of vulvovaginitis, often accompanied by vaginal discharge, soreness, and burning, affecting women of all ages 1, 2
• Vulvovaginal candidiasis (VVC) is characterized by white, thick discharge resembling cottage cheese, normal vaginal pH (≤4.5), and intense vulvar itching and burning, according to the Centers for Disease Control and Prevention (CDC) 1, 3

Types of Vulvovaginitis and Their Specific Symptoms

• The CDC recommends that vulvovaginal candidiasis be diagnosed based on symptoms and physical examination findings, including erythema and swelling of vulvovaginal tissues, and affects approximately 75% of women at least once in their lifetime 1, 3
• Trichomoniasis is characterized by diffuse, malodorous, yellow-green discharge and vulvar irritation, with the American Academy of Family Physicians noting that treatment of sexual partners is essential to prevent reinfection 2

Diagnosis

• The CDC states that clinical diagnosis of vulvovaginitis is based on symptoms and physical examination findings, with microscopic examination of vaginal secretions using 10-20% potassium hydroxide (KOH) preparation to show yeast forms or pseudohyphae for candidiasis 1, 3, 4
• Vaginal pH testing is used to diagnose bacterial vaginosis and trichomoniasis, with a normal pH of ≤4.5, according to the CDC 3

Treatment Options

• The CDC recommends topical azoles, such as butoconazole, clotrimazole, and miconazole, for uncomplicated VVC, with treatment duration ranging from 3 to 14 days 5, 3
• For complicated VVC, the CDC suggests longer initial therapy (7-14 days of topical therapy or fluconazole 150mg repeated after 3 days), with maintenance regimens for recurrent cases, including clotrimazole 500mg vaginal suppositories once weekly or fluconazole 100-150mg once weekly 5, 6, 1
• The American Academy of Family Physicians recommends oral metronidazole 2g as a single dose for trichomoniasis, with treatment of sexual partners essential to prevent reinfection 2

Special Considerations

• Pregnant women with VVC should only use 7-day topical azole therapies, according to the American Academy of Family Physicians 1
• HIV-infected women should receive the same treatment as non-HIV-infected women, with the CDC noting that self-medication with OTC preparations should only be advised for women previously diagnosed with VVC experiencing the same symptoms 1, 4, 5, 6

Treatment of Resistant Vaginal Discharge with Itching

Evaluation and Treatment Protocol

• The American Academy of Family Physicians recommends that in cases of vaginal discharge with itching resistant to initial treatment, the condition should be reclassified as complicated vulvovaginal candidiasis and treated with prolonged topical azole therapy (7-14 days) or fluconazol 150 mg repeated after 3 days, followed by a maintenance regimen for 6 months if symptoms persist 7
• The American Academy of Family Physicians suggests verifying host factors such as uncontrolled diabetes, immunosuppression, pregnancy, or HIV infection, which automatically classify the case as complicated 8, 7
• The Centers for Disease Control and Prevention recommends confirming therapeutic compliance and ruling out reinfection from untreated sexual contact 7
• The American Academy of Family Physicians recommends azole topical therapy for 7-14 days (clotrimazole, miconazole, terconazole) for initial extended treatment 9, 10
• The American Academy of Family Physicians suggests that once initial remission is achieved, clinical and mycological control should be maintained with a regimen such as clotrimazole, fluconazol, ketoconazol, or itraconazol for 6 months 8, 7
• The American Academy of Family Physicians recommends considering treatment of the sexual partner in cases of recurrent infections, although candidiasis is not typically considered a sexually transmitted infection 8, 7
• The Centers for Disease Control and Prevention suggests that patients with HIV receive the same treatment as patients without HIV 8, 7, 10
• The American Academy of Family Physicians recommends avoiding common errors such as not extending the duration of initial treatment, omitting the maintenance regimen, and not evaluating and treating the sexual partner 8, 7
• The American Academy of Family Physicians suggests that pregnant women use only topical azoles for 7 days and never use fluconazol orally 8

Treatment of Concurrent Vaginal Candidiasis and Bacterial Vaginosis

Diagnostic Confirmation

• The Centers for Disease Control and Prevention recommends measuring vaginal pH using narrow-range pH paper and performing saline wet mount microscopy to identify clue cells characteristic of bacterial vaginosis and assess for inflammatory cells, as well as performing 10% KOH preparation to visualize yeast or pseudohyphae confirming candidiasis 11, 12
• The combination of creamy, smelly discharge with irritation strongly suggests concurrent infections, as candidiasis alone produces white, thick discharge with normal pH, while bacterial vaginosis produces malodorous discharge with elevated pH 11

Treatment Protocol for Concurrent Infections

• The Centers for Disease Control and Prevention recommends oral metronidazole 500 mg twice daily for 7 days as the first-line treatment for bacterial vaginosis 11
• The Infectious Diseases Society of America recommends single-dose oral fluconazole 150 mg for uncomplicated candidiasis, achieving a 55% therapeutic cure rate 13
• For complicated candidiasis, the Infectious Diseases Society of America recommends using topical azole therapy for 7-14 days or fluconazole 150 mg every 72 hours for 3 doses 13
• Topical azole options include clotrimazole 1% cream, miconazole 2% cream, or terconazole 0.4% cream 12, 14

Critical Treatment Considerations

• The Centers for Disease Control and Prevention notes that metronidazole treatment can precipitate vulvovaginal candidiasis in 12.5-30% of patients, making concurrent antifungal therapy essential 11
• The Centers for Disease Control and Prevention recommends treating sexual partners with symptomatic balanitis, but not routinely for candidiasis 14
• Partner treatment has not been shown to reduce recurrence rates for bacterial vaginosis 11

Special Populations

• The Centers for Disease Control and Prevention recommends using only 7-day topical azole therapy for candidiasis and oral metronidazole for bacterial vaginosis in pregnant women 12, 14
• The Infectious Diseases Society of America recommends identical treatment regimens for HIV-infected patients as HIV-negative patients, with equivalent expected cure rates 13, 12
• For recurrent infections, the Infectious Diseases Society of America recommends maintaining with fluconazole 150 mg weekly for 6 months after achieving initial cure 13

Treatment Decision for Asymptomatic Yeast and Clue Cells

Diagnostic Considerations

• The CDC recommends not treating based solely on microscopic findings of few yeast and rare clue cells without accompanying symptoms, as approximately 10-20% of women normally harbor Candida species in the vagina without infection 15
• Normal vaginal pH (≤4.5) should be present, according to the CDC 15
• The CDC states that asymptomatic colonization with "few yeast" represents normal flora, not infection requiring treatment, and reassures that low levels of yeast and occasional clue cells represent normal vaginal flora variation 15

Clinical Decision Algorithm

• If the patient is asymptomatic, no treatment is indicated, and the patient should be reassured that low levels of yeast and occasional clue cells represent normal vaginal flora variation, as stated by the CDC 15

Critical Pitfalls to Avoid

• The CDC advises never to treat microscopic findings without clinical correlation, as this leads to unnecessary medication exposure and potential adverse effects 15
• The CDC recommends avoiding self-medication recommendations, stating that self-medication with OTC preparations should only be advised for women previously diagnosed with VVC experiencing identical recurrent symptoms 15
• The CDC notes that VVC may coexist with STDs, and maintains that appropriate clinical suspicion and testing should be undertaken when indicated 15

When to Reassess

• The CDC instructs patients to return only if symptoms develop or persist, and any woman who develops symptoms after initial negative evaluation should undergo repeat wet mount examination 15

CDC Guideline Summary for Diagnosis and Management of Vulvovaginal Candidiasis

Diagnostic Approach

• Measure vaginal pH with narrow‑range pH paper; a pH ≤ 4.5 supports VVC and helps differentiate it from bacterial vaginosis or trichomoniasis (pH > 4.5). – CDC recommendation. 16
• Perform a wet‑mount microscopy with 10 % KOH; yeast forms or pseudohyphae are visualized in approximately 50‑70 % of true VVC cases. – CDC recommendation. 16
• Assess clinical signs such as vulvar erythema, thick white “cottage‑cheese” discharge, and lack of malodor; these findings strongly favor VVC over other causes. – CDC recommendation. 16
• Confirm the absence of inflammatory signs; a painless white discharge with normal pH makes bacterial vaginosis and trichomoniasis unlikely. – CDC recommendation. 17

First‑Line Pharmacologic Options (Uncomplicated VVC)

• Topical azole regimens (7‑day course):
  
  • Clotrimazole 1 % cream, 5 g intravaginally daily. – CDC recommendation. 16
  • Miconazole 2 % cream, 5 g intravaginally daily. – CDC recommendation. 16
  • Terconazole 0.4 % cream, 5 g intravaginally daily. – CDC recommendation. 16
• Single‑dose topical agents (for mild‑to‑moderate disease only): clotrimazole 500 mg vaginal tablet or tioconazole 6.5 % ointment. – CDC recommendation. 16

Management Considerations

• Do not treat based solely on microscopic detection of Candida when the patient is asymptomatic; 10‑20 % of individuals harbor Candida without infection. – CDC recommendation. 16
• Asymptomatic colonization does not require therapy, even if yeast is seen on microscopy. – CDC recommendation. 16
• Routine treatment of sexual partners is not advised because VVC is not sexually transmitted and partner therapy does not lower recurrence rates. – CDC recommendation. 16

Follow‑Up and Patient Instructions

• Advise patients to seek follow‑up only if symptoms persist after therapy or recur within two months. – CDC recommendation. 16

Common Pitfalls to Avoid

• Avoid recommending over‑the‑counter self‑medication unless the patient has a prior confirmed VVC diagnosis and experiences identical recurrent symptoms. – CDC recommendation. 16
• Do not rely on symptoms alone to diagnose VVC; microscopic confirmation is essential because clinical presentation is not specific. – CDC recommendation. 16
• Maintain vigilance for co‑existing sexually transmitted infections; test for STIs when clinically indicated. – CDC recommendation. 16

Guideline Recommendations for Diagnosis and Management of Refractory Vulvovaginal Candidiasis

Diagnostic Work‑up

Reasons for OTC Treatment Failure

Management of Confirmed Infections

Complicated VVC caused by Candida albicans

Infections due to Non‑albicans Candida (e.g., C. glabrata)

Concurrent Bacterial Vaginosis

Assessment of Predisposing Factors

Partner Evaluation